Better Space Stock: Rocket Lab vs. AST SpaceMobile

Rocket Lab and AST SpaceMobile are advancing complementary segments of the growing space economy: Rocket Lab (RKLB) is the U.S. market's second-most-used launch provider with 81 launches to date, a >$1 billion backlog, an operational small-lift Electron vehicle and a medium-lift Neutron expected this year (timeline may be delayed), and is forecast by analysts to grow revenue from ~$600M in 2025 to ~$1.5B by 2028 and reach profitability in 2027. AST SpaceMobile (ASTS) is building a BlueBird satellite constellation to provide direct-to-cellphone connectivity, has commercial agreements with carriers including AT&T and Verizon plus a $43M Space Development Agency-related award, and is projected to grow revenue from ~$57M in 2025 to ~$1.94B in 2028 with profitability no earlier than 2028; it targets 45–60 satellites in orbit by end-2026 and ~90 for global coverage. The author favors Rocket Lab for nearer-term revenue generation and earlier expected profitability, while both firms are positioned to benefit from a McKinsey-forecasted expansion of the global space economy to ~$1.8 trillion by 2035.

Analysis

Market structure: Rocket Lab (RKLB) benefits as a diversified launcher + space-systems business with a stated >$1B backlog, giving it nearer-term cash-flow optionality versus pure-play constellations. AST SpaceMobile (ASTS) is a high-execution-risk beneficiary if it hits 45–60 BlueBird sats by end-2026, but faces direct competition from SpaceX/Starlink and mobile-network-operator bargaining power (AT&T/VZ deals dilute pricing power). Lower per-kg launch costs compress pricing for small launches, pressuring margin-less rideshare players while advantaging vertically integrated players that scale (RKLB if Neutron succeeds). Cross-asset: expect elevated equity volatility and widened credit spreads for capital-hungry constellation plays (ASTS), supportive flows into defense primes and suppliers; options implied vol will rise into RKLB timeline update and ASTS deployment windows.

Risk assessment: Tail risks include launch failure, spectrum/regulatory pushback, and equity dilution — any single failed ASTS launch or Neutron delay could trigger >40% drawdowns. Immediate (days): RKLB share reaction to the timeline update this month; short-term (1–6 months): ASTS satellite deployment cadence and capital raises; long-term (2027–2028): profitability convergence (RKLB 2027, ASTS 2028) depends on converting backlog and ARPU realization. Hidden dependencies: reliance on a few telco partners, supply-chain bottlenecks for Neutron, and SpaceX pricing externalities. Key catalysts: Neutron maiden attempt, FCC/DoD contract awards, ASTS achieving 45 sats and first commercial roaming revenue.

Key Decisions for Investors

• Establish a 2–3% long position in Rocket Lab (RKLB) sized to portfolio risk, complemented by buying 12–18 month LEAP calls; set a hard stop-loss at -25% if Rocket Lab misses an updated Neutron timeline pushed beyond Q3 2026.
• Initiate a pair trade: long RKLB (1.5% notional) and short ASTS (1.5% notional) to capture execution and capital-structure asymmetry; trim both legs if ASTS announces >1 material equity raise or if RKLB demonstrates Neutron success within 90 days of its update.
• Avoid increasing direct equity exposure to ASTS until it confirms 45–60 BlueBird satellites in orbit and posts recurring commercial revenue; if speculating pre-milestone, limit size to 0.5–1% via OTM calls expiring 9–12 months after the first 45-sat confirmation.
• Rotate 1–2% of portfolio weight from speculative constellation equities into diversified aerospace suppliers and defense primes with stable backlog (e.g., space-systems suppliers), and monitor credit spreads: consider buying short-dated high-yield protection if ASTS draws >$100M in fresh debt within 6 months.